Benjamin Graham Detailed Fundamental Analysis

According to Validea's guru fundamental report, REGENERON PHARMACEUTICALS INC (REGN) receives a rating of 86% based on their Value Investor model, which is based on the strategy of Benjamin Graham. The report indicates that REGN, a large-cap value stock, passes key criteria such as sales, current ratio, long-term debt in relation to net current assets, long-term EPS growth, and P/E ratio, but fails the price/book ratio test. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Analysis

Regeneron Pharmaceuticals (REGN) has received a favorable rating of 86% from Validea's Value Investor model, which is based on the deep value principles of Benjamin Graham. This score indicates notable interest from a quantitative value perspective. The analysis highlights that REGN, a large-cap biotechnology stock, successfully passes multiple key fundamental tests, including criteria for sales, current ratio, long-term EPS growth, and maintaining low long-term debt relative to net current assets. Furthermore, the company's Price-to-Earnings (P/E) ratio is considered attractive under this model. The single point of failure is its Price-to-Book (P/B) ratio, which does not meet the strict criteria of the Graham strategy. This suggests that while the company exhibits strong characteristics of a classic value investment based on earnings and balance sheet health, its valuation based on book value is elevated.

Key Decisions for Investors

• Value-oriented investors should consider REGN for further due diligence, as it aligns with most criteria of a classic Benjamin Graham-style investment, particularly its strong earnings growth and low debt load.
• A key follow-up action is to investigate the elevated Price-to-Book ratio, determining if it is justified by intangible assets like intellectual property, which are common in the biotech sector, or if it represents a genuine valuation risk.
• Investors should supplement this quantitative value screen with qualitative analysis of REGN's drug pipeline, competitive positioning, and sector-specific catalysts, as the model does not account for these future growth drivers.